Objective Overweight and heightened sympathetic activity are more common in hypertensive than normotensive subjects. â-adrenoceptor down-regulation has been described in hypertension. We tested the hypothesis that chronic sympathetic overactivity impairs â-adrenergicmediated thermogenesis and thereby favours gain of weight in hypertension.
Objective Overweight and heightened sympathetic activity are more common in hypertensive than normotensive subjects. â-adrenoceptor down-regulation has been described in hypertension. We tested the hypothesis that chronic sympathetic overactivity impairs â-adrenergicmediated thermogenesis and thereby favours gain of weight in hypertension.
Participants The study included 13 hypertensive subjects aged 35.3 6 7.9 years and 25 normotensive subjects of control of similar age.
Methods To measure â-adrenergically mediated haemodynamic, metabolic and thermogenic responsiveness, increasing doses of isoproterenol diluted in 2.5 ml saline were injected as intravenous boluses (0.1, 0.25, 0.5, 1.0 and 2.0 ìg/m 2 ). On a separate day, isoproterenol was infused continuously intravenously in increasing doses (10, 20 and 40 ng/kg per min), each dose for 30 min.
Results The sitting heart rate and body mass were greater in hypertensives (P 0.000, and P 0.005, respectively). The heart rate responses to 1 and 2 ìg/m 2 isoproterenol bolus (P 0.01 and P 0.03, respectively) were reduced in hypertensives. The energy expenditure (P 0.002) and oxygen consumption (P 0.0004) increase with 40 ng/kg per min isoproterenol infusion, and glucose and phosphate responses at both 20 (P 0.01 and P 0.05) and 40 (P 0.001 and P 0.02) ng/kg per min isoproterenol infusion were attenuated in hypertensives. The baseline heart rate negatively correlated with heart rate (P 0.015) response to isoproterenol bolus and blood pressure (P 0.02) response to isoproterenol infusion. The urinary noradrenaline negatively correlated with heart rate response to isoproterenol bolus (P 0.001), and with systolic blood pressure (P 0.02) and energy expenditure responsiveness to isoproterenol infusion (P 0.04). Furthermore, plasma noradrenaline negatively correlated with heart rate responsiveness to isoproterenol bolus (P 0.004).
Introduction
An association of increased sympathetic tone with overweight has been described in patients with borderline or stage 1 hypertension [1] [2] [3] . Moreover, high blood pressure has been found to be a precursor of obesity in some epidemiologic studies [3] [4] [5] . The Framingham study reported that, among subjects who were initially weightmatched, those with higher initial blood pressure values later gained more weight compared to subjects with lower blood pressure [4] . In the Tecumseh population, subjects who in the fourth decade of life had hypertension already exhibited elevated blood pressure values at 7 years of age but only later became overweight [3, 5] .
Data from Masuo et al. [6, 7] strongly suggest that sympathetic overactivity may be the linchpin connecting the development of both future blood pressure elevation and increase in body weight. These authors followed a cohort of healthy subjects up to 10 years and found that subjects whose blood pressure increased with time initially had elevated heart rate and plasma noradrenaline values. Similarly, an early elevation of noradrenaline predicted future increases in weight.
There is ample evidence that â-adrenergic stimulation increases the basal metabolic rate [8] and that â-blockade decreases the thermogenic response to food [9] . Furthermore, substantial evidence has accumulated demonstrating that â-adrenergic responsiveness is decreased in hypertension [5, 10, 11] . Based on these facts, we hypothesized that increased sympathetic tone may elicit a down-regulation of â-adrenergic haemodynamic, metabolic and energy expenditure responsiveness in hypertension, which in turn may lead to excessive gain of weight by impairing the ability of the patient to dissipate excess calories.
In this study, we tested the feasibility of this concept by designing a comprehensive study to evaluate the relationship between indices of sympathetic tone at baseline and â-adrenergic responsiveness in stage 1 hypertensive patients and in normotensive subjects.
Methods

Subjects
We studied 13 subjects with stage 1 essential hypertension and 25 normotensive control subjects of similar age. All subjects were aged 18 years or older and were recruited by advertisement. Patients with secondary forms of hypertension, history of proven dysrhythmia, coronary artery disease, congestive heart failure, abnormal thyroid function and diabetes mellitus were excluded. Six hypertensive subjects had never taken any antihypertensive treatment before the study. In the other seven subjects, pharmacological treatment was withdrawn for at least 3 weeks before the study.
Protocol
The study was approved by the University of Michigan Institutional Review Board and was performed at the University of Michigan Clinical Research Center. All procedures were in accordance with institutional guidelines. Participants provided their written informed consent. The protocol comprised of three scheduled sessions at least 1 week apart within a 6-week period. All sessions took place at 0830 h in a quiet room maintained at 248C. Subjects agreed not to eat, smoke, drink alcohol or use caffeine after they had an early dinner on the previous day.
Day 1
Subjects read the informed consent form and all tests were described to them in detail. If a subject gave consent, a physical examination was performed, fasting blood samples for laboratory exams were drawn, a 12-lead electrocardiogram (ECG) was recorded, and 24-h urinary collection for catecholamine measurement was scheduled.
Day 2
After 15-min rest, blood pressure (with a mercury sphygmomanometer) and heart rate (by pulse palpation for 30 s) were measured in the recumbent and sitting position. The average of three consecutive measurements was calculated for subsequent analysis. Anthropometric measurements included height, weight and skinfold thickness. Skinfold thickness was measured in triplicate at the triceps and biceps, and at subscapular and suprailiac areas with a manual caliper, and the sum of the 12 measurements was defined as skinfold thickness.
A 21-gauge cannula was placed in a large antecubital vein of the non-dominant arm and kept patent with 0.9% saline. Increasing doses of isoproterenol diluted in 2.5 ml saline were injected as intravenously boluses (0.1, 0.25, 0.5, 1.0 and 2.0 ìg/m 2 ). Each dose was injected over 15 s and flushed with 2.5 ml of saline for 15 s. A 10-min or longer period was interposed between subsequent doses to allow the heart rate to return to baseline. For each isoproterenol bolus dose, heart rate response was calculated from ECG tracings by subtracting the baseline measurement from the respective peak value. Whereas the heart rate was monitored continuously by ECG, the blood pressure was taken at the end of each step. The protocol required stopping the procedure if the heart rate exceeded 130 b.p.m. or the systolic blood pressure exceeded 200 mmHg. No other adverse events caused interruption of isoproterenol injections.
Heart rate response to isoproterenol bolus was used as a measure of sensitivity of cardiac â-adrenoreceptors because the heart rate response to isoproterenol infusion might have reflected secondary metabolic and haemodynamic adjustments to prolonged adrenergic stimulation.
Day 3
A 21-gauge cannula was placed in a large antecubital vein of both arms for isoproterenol infusion and blood sampling, respectively, and kept patent with 0.9% saline.
calorimetry with a circuit ventilated hood system (Deltatrac II; Sensormedics Corporation, Yorba Linda, California, USA). The energy expenditure was calculated according to the abbreviated formula provided by Weir [12] . O 2 consumption and CO 2 production (integrated over 1 min) were measured for 30 min. Baseline values were calculated by averaging the readings taken during the last 10 min.
After 30 min of rest, blood was drawn for plasma adrenaline, noradrenaline, insulin, glucose, potassium and phosphate assessment without applying a tourniquet.
After the period of resting measurement, isoproterenol was infused intravenously, continuously, in increasing doses (10, 20 and 40 ng/kg per min) for 30 min for each dose.
At the end of each infusion step, O 2 consumption and CO 2 production (last 10-min averages), blood pressure and heart rate were recorded, and blood for biochemical analyses was drawn. If the heart rate exceeded 130 b.p.m. or the systolic blood pressure exceeded 200 mmHg or, if the subject was not comfortable with isoproterenol-induced symptoms, the procedure was terminated.
Analytical procedures
Serum potassium and phosphate determinations were performed by standard clinical laboratory methods on a Vitros 950 automated chemistry analyser (Ortho-Clinical Diagnostics, Raritan, New Jersey, USA). Plasma insulin was measured by immunoassay with a chemiluminescent signal detection reaction on an Immulite Analyser (Diagnostic Products Corporation, Los Angeles, California, USA). Plasma and urinary catecholamine levels were determined by high-performance liquid chromatography with electrochemical detection according to the method of Riggin and Kissinger [13] .
Statistical analysis
Data are presented as mean AE SD for continuous variables and as proportions for categorical variables. Log-transformation was performed for non-normally distributed variables. Student's t-test was used for comparisons of anthropometric, clinical and laboratory data between the two groups. P < 0.05 (two-tailed) was considered statistically significant. To account for the within-subject correlation, a repeated measures analysis for continuous outcomes was performed using SAS PROC MIXED procedure [14] . Pearson's correlation coefficient was used to assess the relationship between independent variables. Data management and analysis were performed with SAS for Windows statistical software, version 6.12 (SAS Institute Inc, Cary, North Carolina, USA).
Results
Baseline data
Baseline characteristics in the two groups of subjects are shown in Table 1 . The two groups were similar in respect to mean age. Hypertensive patients had higher heart rate, body weight, body mass index (BMI), skinfold thickness and glucose than control subjects. Resting plasma and urinary catecholamines, insulin, and plasma lipids did not differ between hypertensive and normotensive subjects. No significant differences in alcohol or tobacco consumption were found between the two groups. Table 2 shows the relationship of baseline measures of sympathetic tone with blood pressure and anthropometric indices in the entire study population. The heart rate strongly and consistently correlated with systolic blood pressure, weight, BMI and skinfold thickness. Correlations of urinary norCopyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. adrenaline tended in the same direction, but only the correlation with weight reached a significant level. Plasma noradrenaline showed the same tendency but none of the correlations reached the P < 0.05 level. Plasma noradrenaline correlated positively with heart rate (r ¼ 0.46, P , 0.004).
â-adrenergic responsiveness to isoproterenol Isoproterenol bolus test
Heart rate responses to increasing isoproterenol bolus doses are shown in Fig. 1 . In hypertensive patients, heart rate responses were lower than in normotensive subjects at the two highest doses.
Isoproterenol infusion test
Energy expenditure and oxygen consumption responses to stepwise isoproterenol infusion are shown in Figs 2 and 3. In hypertensive patients, both responses were blunted at the highest infusion rate. Metabolic, electrolyte and blood pressure responses to isoproterenol infusion are summarized in Table 3 . The glucose increase and phosphate decrease to 20 and 40 ng/kg per min infusion rates were significantly attenuated in hypertensive subjects. The potassium decrease at the 40 ng/ kg per min infusion rate was also reduced in hypertensives, but the difference did not reach statistical significance. The systolic blood pressure and the pulse pressure increase to the isoproterenol 40 ng/kg per min infusion rate was blunted in hypertensive subjects.
Correlations
The correlations between indices of resting sympathetic nervous system tone (heart rate, plasma and
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. Heart rate response to isoproterenol bolus test in hypertensive patients and normotensive subjects. Data are mean AE SEM. **P ¼ 0.011, ***P ¼ 0.0095 for group difference. Among the controls, one subject was discontinued after the first bolus, one after the second, one after the third, and three after the fourth. Among the hypertensives, two subjects were discontinued after the second bolus, two after the third, and one after the fourth. Energy expenditure response to isoproterenol intravenous infusion in hypertensive patients and normotensive subjects of control. Data are mean AE SEM. EE, Energy expenditure. *P ¼ 0.002 for group difference. Due to heart rate safety parameters, the procedure was stopped in three control subjects after the first infusion rate, and in five after the second. Among the hypertensives, the procedure was stopped in two subjects after the first infusion rate, and in five after the second.
Hypertensives
24-h urinary noradrenaline) with â-adrenergic responsiveness to the highest isoproterenol bolus or infusion rate are presented in Table 4 . Resting heart rate correlated negatively with the isoproterenolinduced increases in heart rate, systolic blood pressure, serum glucose, phosphate and energy expenditure, and showed a positive correlation with the expected decrease in serum potassium. These relationships reached statistical significance for the correlations of resting heart rate with changes in heart rate, systolic blood pressure and glucose. The Pvalue of the correlation of resting heart rate with the decrease in potassium was of borderline significance.
Similar linear trends were seen for resting plasma and urinary noradrenaline, but only the negative relationships of plasma noradrenaline (r ¼ À0.55, P ¼ 0.004) and urinary noradrenaline (Fig. 4) with isoproterenolinduced increase in heart rate, and the negative relationship of urinary noradrenaline with increase in systolic blood pressure (SBP) (r ¼ À0.59, P ¼ 0.017) and energy expenditure (Fig. 4) were statistically significant.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. Oxygen consumption response to isoproterenol intravenous infusion in hypertensive patients and normotensive subjects of control. Data are mean AE SEM. VO 2 , Oxygen consumption. ***P ¼ 0.0004 for group difference. Dropouts are as indicated in Fig. 2 . Table 4 Pearson's correlations of indices of resting sympathetic nervous system tone (heart rate, plasma and 24-h urinary noradrenaline), with â-adrenergic mediated responses to the highest isoproterenol bolus dose (heart rate) and infusion rate (systolic blood pressure, serum glucose, potassium, phosphate and energy expenditure) in the whole study population˜H , Change; HR, heart rate; SBP, systolic blood pressure; G, serum glucose; K, serum potassium; Phos, serum phosphate; EE, energy expenditure. Non-normally distributed variables were log transformed.
Discussion
The results of the present study show that both haemodynamic and metabolic responses to â-adrenergic stimulation with isoproterenol are attenuated in patients with stage 1 hypertension. The blunted increase in heart rate and systolic blood pressure points to decreased â 1 -responsiveness in our hypertensive subjects. Moreover, the reduced response of energy expenditure, oxygen consumption, glucose and electrolytes to isoproterenol infusion indicates that also the â 2 -adrenoceptors were downregulated in these subjects [8] . These findings confirm previous observations from the literature that â-adrenergic-mediated cardiac, vascular, electrolyte and glucose responses are blunted in hypertension [10, 11, 15, 16] , and further extend them by also showing that oxygen consumption and energy expenditure responses are impaired in hypertensive subjects. Additionally, our study is the first to demonstrate all these abnormalities in the same patient group.
In the combined population of hypertensive and control subjects, a faster resting heart rate was associated with lesser haemodynamic and metabolic responses to isoproterenol. Moreover, higher 24-h urinary norepinephirine level was associated with smaller heart rate, SBP and energy expenditure responses to isoproterenol. The finding that â-adrenergic responsiveness was inversely proportional to the baseline sympathetic tone suggests that decreased â-adrenergic responses reflect a physiological down-regulation of â-adrenoceptors in response to the higher sympathetic activity in patients with hypertension [5] . Furthermore, these findings support the feasibility of our concept that a less efficient â-adrenergically-mediated thermogenic dissipation of excess calories might facilitate the development of overweight and obesity in hypertension. Our hypertensive subjects were overweight, had signs of increased sympathetic tone and, in the entire study population, the baseline markers of sympathetic tone (mainly heart rate) correlated with body weight, adiposity and blood pressure values. The basic energy equation postulates that if the caloric intake exceeds the energy expenditure, then excess calories will be stored as fat. This general concept simplifies a rather complex underlying feedback mechanism that includes afferent signals, a controller that senses the afferent inputs and transduces them, and then activates efferent receptors. Landsberg et al. [17] demonstrated that excessive feeding increases plasma glucose and insulin levels in rats. This elicits an enhanced sympathetic tone through a direct action on the central nervous system. In their view, the sympathetic response to feeding is an important compensatory mechanism to dissipate excess calories and maintain a reasonably steady body weight. Among different receptors, patterns of all three â-adrenoreceptor subtypes and their distribution in tissues play an important role in mediating energy balance. Adipocytes have adrenergic receptors and it has been shown that sympathetic neural activity stimulates lipolysis and decreases triglyceride-rich lipoprotein accumulation in white adipose tissue [18] . Resting metabolic rate, which accounts for 50-70% of human daily energy expenditure, increases following catecholamine infusion and decreases after several days of â-adrenergic blockade [8, 9] . Similarly, Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. Pearson's correlations of baseline 24-h urinary noradrenaline with heart rate responsiveness at the highest isoproterenol bolus dose and log energy expenditure responsiveness at the highest isoproterenol infusion rate in the whole study population. Several subjects are missing because they did not reach the highest isoproterenol dose. HR, Heart rate; EE, energy expenditure; NA, noradrenaline. Correlation coefficients and P-values were calculated from log-transformed data.
the facultative component of diet-induced thermogenesis is mediated by the sympathoadrenal system [19] . Thus, â-adrenoreceptor stimulation tends to increase the energy expenditure and decrease the fat accumulation. All three â-adrenoceptors subtypes are involved in sympathetic-induced thermogenesis [20] . In humans, approximately 30-40% of this response is due to â 3 -adrenoreceptor activation [21] .
In animal models, the â 3 -adrenoreceptor appears to resist receptor desensitization [22] . However, when all three human â-adrenoceptors were expressed in immortalized brown adipocites [23] , a sustained adrenergic stimulation caused them to downregulate. Furthermore, the thermogenic response to isoproterenol was attenuated after sustained â-adrenergic stimulation in normal volunteers [24] . â-adrenergic down-regulation may explain why a number of â 3 -adrenoceptor agonists did not live up to their potential as anti-obesity agents [25] . Such drugs were highly selective for the human â 3 -adrenoceptors in vitro [26, 27] and showed lipolitic and thermogenic activity after a single-dose administration in vivo [28] . However, after longstanding oral administration, they failed to affect energy expenditure and body weight in obese subjects [25, 29] .
Our data on depressed energy expenditure and oxygen consumption with isoproterenol infusions suggest that patients with hypertension might be prone to future increase of weight because their capacity to dissipate excess calories via â-adrenoceptor-mediated calorie dissipation is diminished. Many borderline and stage 1 hypertensives show sympathetic overactivity and are overweight. We think that the â-receptor responsiveness is decreased because of the enhanced sympathetic tone in hypertension. In longitudinal studies, it has been demonstrated that plasma noradrenaline concentrations predict both future blood pressure elevation and weight gain in lean normotensives [5] [6] [7] . Downregulation of â-adrenoceptor-mediated thermogenic responses may be the mechanism by which longstanding sympathetic overactivity favours weight gain together with blood pressure elevation. We cannot claim that this is the only mechanism via which hypertension and overweight are associated. In some patients, a defect in the regulation of appetite may be the primary factor. Landsberg et al. [17] emphasized the primacy of eating behaviour in the determination of obesity, the metabolic syndrome and the subsequent elevation in blood pressure, suggesting that obesity is linked with hypertension through activation of the sympatho-adrenal system. In such cases, insulin resistance and the related increase in sympathetic tone are likely to play a role in the development of subsequent hypertension. However, regardless of where the process starts, sympathetic overactivity is postulated in most proposed hypotheses that link hypertension and obesity. From that viewpoint, the down-regulation of metabolic â-adrenergic responses may further enhance the vicious cycle of body weight increase in the hypertensive patient.
Limitations of the study
The main limitation to our conclusion is the crosssectional nature of our protocol and the significant difference in BMI between the normotensive and the hypertensive subjects. Follow-up studies might be more appropriate to clarify the association between sympathetic overactivity and â-adrenoreceptor responsiveness. In such studies, it might be ideal to select a control group of similar body weight as in hypertensive subjects. However, the greater body weight shown by the hypertensive subjects in the present study was the result of a selection based only on the hypertensive status. Another possible limitation is that we studied the effects of isoproterenol, a non-selective â-adrenoceptor agonist. Our study protocol does not permit conclusions about the relative contribution of various â-adrenoreceptor subclasses to the thermogenic response, nor can we discern which â-receptors are more or less prone to down-regulation. Finally, the present data were obtained in young-to-middle-age subjects and, thus, these results cannot be extrapolated to older individuals. However, it has been demonstrated that the attenuation of the chronotropic response to isoproterenol in hypertension increases with increasing age [30] . Therefore, decreased â-adrenergic responsiveness might also be responsible for weight gain in older hypertensive patients.
Conclusion
Our results show that sympathetic overactivity causes a decreased â-adrenoceptors responsiveness in hypertension and that, in turn, this decreases oxygen consumption and energy expenditure. The decreased sympathetically-mediated energy expenditure might explain why patients with hypertension are prone to gaining weight. Controlling weight in hypertension is an eminently sensible goal. It could diminish the need for pharmacological treatment of high blood pressure and improve cardiovascular prognosis of the patient. However, in practice, dietary attempts to achieve longterm weight control in hypertension have uniformly been unsuccessful. The possibility that â-adrenoceptor down-regulation diminishes an individual's ability to dissipate calories and that, in many hypertensive patients, the gain of weight might be an inevitable consequence of abnormal physiology, ought to redirect our approach to the problem. In the basic science of weight control, research into prevention of â-adrenoreceptor down-regulation might yield better results than the present search for a better â-adrenergic agonist. In clinical practice, acting on sympathetic overactivity as the proximate cause of receptor downregulation might be a more useful proposition than demanding that the patients lose weight, which is a task that most of them could not possibly fulfill.
